Journal article
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
Abstract
BACKGROUND: World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19).
METHODS: We randomly assigned inpatients with Covid-19 equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local …
Authors
Pan H; Peto R; Henao-Restrepo A-M; Preziosi M-P; Sathiyamoorthy V; Abdool Karim Q; Alejandria MM; Hernández García C; Kieny M-P; Malekzadeh R
Journal
The New England Journal of Medicine, Vol. 384, No. 6, pp. 497–511
Publisher
Massachusetts Medical Society
Publication Date
February 11, 2021
DOI
10.1056/nejmoa2023184
ISSN
0028-4793
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Adenosine MonophosphateAgedAlanineAntiviral AgentsCOVID-19Drug Therapy, CombinationFemaleHospital MortalityHospitalizationHumansHydroxychloroquineIntention to Treat AnalysisInterferon beta-1aKaplan-Meier EstimateLength of StayLopinavirMaleMiddle AgedRespiration, ArtificialTreatment FailureCOVID-19 Drug Treatment